AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
FPH:
Fisher & Paykel Healthcare Corporation Limited (ASX:FPH) is a market player which leads in dealing with design, production, and marketing of products and services to be used in respiratory and acute care, operation, and to cure sleep apnoea. FPHâs sells its products in more than 120 countries across the globe.
Companyâs spread (Source: Companyâs report)
The company announced its record result for the 2019 financial year, registering a net profit after tax up 10% to NZ$209.2 million, from NZ$190.2 million. Another feather in its cap was the achievement of over NZ$1 billion in revenue, with its operating revenue up by 9% to a record NZ$1,070 million, from NZ$980.8 million. The companyâs total assets amounted to NZ$1,206.7 million and liabilities were NZ$293.5 million.
On the outlook front, the company intends to continuously improve and expand its portfolio. FPH expects a capital expenditure of almost NZ$150 million for 2020. The operating revenue is expected to be nearly NZ$1.15 billion and NPAT to range between NZ$240 million to NZ$250 million.
Below is an excerpt from the cash flow statement:
(Source: Companyâs report)
Share Price Information:
The market capitalisation of the company is A$8.3 billion. The 52-week high and low of the stock is A$15.83 and A$11.28, respectively. The stock traded flat and closed at A$14.470 as of 31st May 2019. In the last one year, the stock has delivered a return of 19.59%, and the YTD return stands at 19.49%.
COH:
Cochlear Limited (ASX: COH) is a player from the healthcare sector and is dedicated to helping people hear and be heard. The company delivers a range of implantable hearing solutions. It aims at innovating its implant facilities to meet customer preferences and needs.
Cochlearâs Global Footprint (Source: Companyâs report)
The company conducted its annual Capital Markets Day at the Macquarie University on 10th May 2019, hosting several analysts. It stated that it had continued R&D investment at approximately 12% of its revenue. The company has been expanding successful direct-to-consumer marketing activities, building referrals via hearing aid and ENT channels and build initiatives to deliver a consistent treatment pathway for adults with acute to profound hearing loss. Its network links surgeons with hearing aid clinics.
Effectiveness of cochlear implants relative to hearing aids (Source: Companyâs profile)
The company is focussing on building awareness and access of products through disciplined investment. It optimises the cost of production, to have a competitive edge. The company uses scale to deliver efficiency gains with the motive to reinvest in market growth activities.
Revenue Growth Drivers (Source: Companyâs profile)
Share Price Information:
The market capitalisation of the company is A$11.35 billion. The 52-week high and low of the stock is A$221.440 and A$155.220, respectively. The stock made an intraday low of A$196.73 and closed at A$200.13 (up by 1.74%), as of 31st May 2019. In the last one year, the stock has delivered a negative return of 0.82%, and the YTD return stands at 12.46%.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
